BioMarin PARP inhibitor advances in race with Tesaro drug
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceutical will begin a Phase III clinical trial for its poly ADP-ribose polymerase (PARP) inhibitor BMN 673 in the treatment of breast cancer earlier than expected, keeping the company in a neck-and-neck race with its closest competitor Tesaro.